Research Frontiers Incorporated — Q3 2012 Form 10-Q Summary
Business Context and Reporting Period
Research Frontiers develops and licenses suspended particle device (SPD) light-control technology for architectural, automotive, marine, aerospace, appliance, eyewear, and other applications. The filing covers the three and nine months ended September 30, 2012. The company operates as a single business segment and remains dependent on commercialization by licensees and related royalty payments.
Financial Results and Position
| Metric | Three Months Ended Sept. 30 | Nine Months Ended Sept. 30 |
|---|---|---|
| Fee income | $471,886 vs. $207,200 | $1,405,292 vs. $492,048 |
| Operating expenses | $972,300 vs. $678,640 | $3,263,891 vs. $2,741,042 |
| Research and development | $369,374 vs. $340,960 | $1,238,764 vs. $1,080,020 |
| Operating loss | $(869,788) vs. $(812,400) | $(3,097,363) vs. $(3,329,014) |
| Net loss | $(866,464), or $(0.04) per share | $(2,459,335), or $(0.13) per share |
| Net cash used in operating activities | Not separately provided | $(1,830,293) vs. $(2,299,247) |
Nine-month fee income increased approximately 186%, primarily because one automotive licensee’s product sales exceeded minimum annual royalty levels, generating $962,610 of additional royalty income. Approximate nine-month operating and net margins were negative 220% and negative 175%, respectively; these percentages are calculated from reported fee income and are not presented as company-reported measures. Third-quarter fee income increased approximately 128%, while the quarterly net loss widened from $801,840 to $866,464.
At September 30, 2012, cash and cash equivalents were $7.97 million, short-term investments were $1.05 million, working capital was $9.32 million, and total shareholders’ equity was $9.41 million. Total liabilities were $343,950, consisting entirely of current liabilities reported in the balance sheet. The filing does not report interest-bearing debt. Cash increased $5.56 million during the first nine months, principally from $6.97 million of net equity financing, partly offset by operating cash use.
Material Changes Versus the Prior Comparable Period
- Nine-month fee income rose $913,244, driven primarily by increased automotive-market sales by one licensee.
- Nine-month operating expenses increased $522,849, reflecting higher payroll and related costs, professional fees, and patent costs.
- Nine-month research and development expense increased $158,744, primarily due to higher payroll, materials, and project costs.
- Nine-month net loss improved by $850,908, largely because of higher fee income and a $613,397 state research and development refundable tax credit recognized in 2012.
- Cash used in operations declined by $468,954 compared with the prior-year period, while equity financing provided $6,974,750.
- The company issued 2,489,227 shares and 497,846 warrants in July and August 2012, increasing shares outstanding and diluting existing holders.
- Revenue concentration increased: five licensees represented approximately 85% of nine-month 2012 fee income, compared with approximately 73% in the comparable 2011 period; one licensee represented approximately 68% in 2012.
Outlook, Risks, Contingencies, and Unusual Items
Management stated that existing cash reserves, budgeted revenues, and the subsequent financing were expected to fund operations without additional funding for the foreseeable future. On October 2, 2012, the company received approximately $5.3 million of net proceeds from a private placement of 1,250,000 shares and warrants to purchase 250,000 shares. The filing also discloses gross proceeds of approximately $5.61 million and a five-year warrant term beginning six months after closing.
The company expects to use cash for research and development, expanded marketing initiatives, and working capital. Management cautioned that additional financing could be required if expenditures exceed expectations and that financing may not be available on favorable terms. Positive cash flow depends on successful commercialization of SPD products by licensees and continuing royalty payments.
The $613,397 tax benefit related to refundable state research and development credits for 2006 through 2009 was unusual and non-recurring in nature; the company does not expect additional credits for years after 2009. Stock-based compensation was $787,538 for the first nine months of 2012, and $1.05 million of related unamortized compensation costs remained at September 30, 2012.
Other risks include dependence on a limited number of licensees, volatility in royalty revenue, delays between licensee product activity and royalty payments, continuing operating losses, technology and competitive developments, patent costs, and uncertainty regarding future financing. The company reported that disclosure controls were effective and that there were no material changes in internal control over financial reporting.
Investor Verification Points
- Verify the sustainability and timing of the automotive licensee’s royalty-driven revenue increase.
- Assess concentration risk from the licensee contributing approximately 68% of nine-month 2012 fee income.
- Reconcile the September 30 cash balance and subsequent October financing with projected operating cash needs.
- Review the dilution implications of the 2012 share issuances and outstanding warrants.
- Confirm that the reported tax benefit is non-recurring and that deferred tax assets remain fully reserved.
- Evaluate whether continuing operating losses and reliance on licensee commercialization could require future capital.